Kymera Therapeutics, Inc. $KYMR Stake Increased by Farther Finance Advisors LLC

Farther Finance Advisors LLC increased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 642.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 624 shares of the company’s stock after buying an additional 540 shares during the period. Farther Finance Advisors LLC’s holdings in Kymera Therapeutics were worth $27,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Kymera Therapeutics in the first quarter worth $68,000. KBC Group NV increased its holdings in Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company’s stock valued at $68,000 after buying an additional 328 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in Kymera Therapeutics by 81.7% in the first quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company’s stock valued at $136,000 after buying an additional 2,230 shares during the last quarter. GAMMA Investing LLC increased its holdings in Kymera Therapeutics by 3,851.5% in the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company’s stock valued at $183,000 after buying an additional 6,509 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in Kymera Therapeutics in the first quarter valued at about $275,000.

Insider Buying and Selling

In related news, CFO Bruce N. Jacobs sold 79,220 shares of the stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.00, for a total value of $3,961,000.00. Following the completion of the transaction, the chief financial officer directly owned 227,409 shares of the company’s stock, valued at $11,370,450. This represents a 25.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the completion of the transaction, the chief executive officer directly owned 660,482 shares of the company’s stock, valued at $32,363,618. This trade represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 16.01% of the company’s stock.

Analyst Ratings Changes

KYMR has been the subject of several research analyst reports. BTIG Research reissued a “buy” rating and issued a $59.00 price objective on shares of Kymera Therapeutics in a report on Thursday, June 26th. Oppenheimer boosted their price objective on Kymera Therapeutics from $53.00 to $63.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. The Goldman Sachs Group raised Kymera Therapeutics to a “strong-buy” rating in a report on Tuesday, July 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Wednesday. Finally, Truist Financial boosted their price objective on Kymera Therapeutics from $53.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, September 30th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.26.

Kymera Therapeutics Trading Down 1.1%

NASDAQ:KYMR opened at $56.29 on Thursday. The firm has a market capitalization of $4.02 billion, a PE ratio of -16.22 and a beta of 2.26. The stock has a 50 day moving average of $46.45 and a 200-day moving average of $39.84. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $59.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The business had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. During the same period last year, the company earned ($0.58) earnings per share. The business’s quarterly revenue was down 55.1% compared to the same quarter last year. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.